Get the Stockscreener App
25.27
3.22%
0.835
Dyne Therapeutics Inc stock is traded at $25.27, with a volume of 1.58M.
It is up +3.22% in the last 24 hours and up +20.47% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$24.44
Open:
$25
24h Volume:
1.58M
Relative Volume:
0.80
Market Cap:
$4.17B
Revenue:
-
Net Income/Loss:
$-451.71M
P/E Ratio:
-7.8345
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
+7.58%
1M Performance:
+20.47%
6M Performance:
+39.84%
1Y Performance:
+153.53%
1-Day Range:
$24.59
$26.05
1-Week Range:
$21.71
$26.05
52-Week Range:
$8.88
$26.05
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
25.25 | 4.04B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
480.54 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.66 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.26 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.12 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.09 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics stock hits 52-week high at 25.06 USD By Investing.com - Investing.com Canada
Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey
Dyne Therapeutics Inc (DYN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dyne Therapeutics Inc (DYN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dyne Therapeutics Inc (DYN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering - Pulse 2.0
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
TradingKey - TradingKey
Skorney: FDA's Sarepta Precedent Makes Dyne DMD Approval 'Impossible' to Deny - finance.biggo.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics Grants New Hires Options on Up to 358,600 Shares - Stock Titan
Dyne Therapeutics grants inducement equity awards for 475,100 shares to 12 new hires - Bitget
DYN Initiated Coverage On by Cantor Fitzgerald -- Rating Set to Overweight - GuruFocus
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway - The Globe and Mail
Dyne Therapeutics closes $431.4 million stock offering - Investing.com
Dyne Therapeutics closes $431.4 million stock offering By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Sells 21M Shares at $20.50 in Offering - Stock Titan
Dyne a new overweight at Cantor on platform for neuromuscular disorders - Seeking Alpha
DYN: Dyne Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating By Investing.com - Investing.com Canada
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling? - Yahoo Finance
Form 424B5 Dyne Therapeutics Inc For: 22 July By Investing.com - Investing.com South Africa
Dyne Therapeutics stock falls 9% after pricing stock offering - Investing.com
Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M - TradingView
Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - MSN
Why Dyne Therapeutics (DYN) Stock Is Down Today - Moomoo
Dyne Therapeutics (DYN) Upsizes Public Offering to $375.15M Amid Stock Decline - GuruFocus
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Why is Dyne Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Dyne Therapeutics stock falls 9% after pricing stock offering By Investing.com - Investing.com Canada
Dyne Therapeutics Prices Upsized $375.2 Million Secondary Offering - marketscreener.com
Form 424B5 Dyne Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
Dyne Therapeutics Stock Tumbles After Hours: Here's Why - Benzinga
Form 424B5 Dyne Therapeutics Inc For: 21 July - Investing.com India
Dyne Therapeutics prices $375 million stock offering By Investing.com - Investing.com Canada
DYN: Increased Offering Size and Pricing Range Announced - GuruFocus
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):